![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication September 21, 2005.
Revised December 27, 2005.
Accepted for publication December 28, 2005.
MDR1/ABCB1, MRP2/ABCC2 and BCRP/ABCG2 are expressed in the liver and intestine and contribute to the disposition of many drugs. Rosuvastatin, an HMG-CoA reductase inhibitor for the treatment of patients with dyslipidemia, is primarily excreted via bile as unchanged drug. The present study was designed to determine if rosuvastatin is transported by MDR1, MRP2 and BCRP. The apparent permeability value for rosuvastatin across MDR1-MDCK cells was low (~ 8 nm/second) and no directional transport was observed. rosuvastatin uptake into control Sf9 membranes and membranes expressing MRP2 was similar in the presence or absence of GSH. In contrast, ATP dramatically stimulated rosuvastatin uptake into membranes expressing BCRP, but not control membranes. Rosuvastatin transport occurred into an osmotically sensitive space and was saturable. An Eadie-Hofstee analysis suggested that there were two transport sites in BCRP, with an apparent Km of 10.8 µM for the high affinity site and 307 µM for the low affinity site. These data demonstrate that rosuvastatin is transported efficiently by BCRP and suggest that BCRP plays a significant role in the disposition of rosuvastatin.
Key words:
ABC transporters, glutathione, MRP, multi-drug resistance, organic anion transport
This article has been cited by other articles:
|
|
 |
|
  P. A. Pham, C. J. L. la Porte, L. S. Lee, R. van Heeswijk, J. P. Sabo, M. M. Elgadi, P. J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner, et al. Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4385 - 4392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zhu, W. M. Awni, B. Hosmane, M. T. Kelly, D. J. Sleep, J. C. Stolzenbach, K. Wan, T. O. Chira, and R. S. Pradhan ABT-335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans J. Clin. Pharmacol., January 1, 2009; 49(1): 63 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kitamura, K. Maeda, Y. Wang, and Y. Sugiyama Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin Drug Metab. Dispos., October 1, 2008; 36(10): 2014 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verhulst, R. Sayer, M. E. De Broe, P. C. D'Haese, and C. D. A. Brown Human Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin Mol. Pharmacol., October 1, 2008; 74(4): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, J. L. Stock, X. Liu, J. Shi, J. W. Van Deusen, D. A. DiMattia, R. G. Dullea, and S. M. de Morais Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds Drug Metab. Dispos., September 1, 2008; 36(9): 1840 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abe, A. S. Bridges, W. Yue, and K. L. R. Brouwer In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 983 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Urquhart, R. G. Tirona, and R. B. Kim Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs J. Clin. Pharmacol., May 1, 2007; 47(5): 566 - 578. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
